Breakfast and Evening Symposia

Please indicate your attendance for the below symposia when registering for the Meeting. Alternatively, please email


Boehringer Ingelheim Pty Limited Evening Symposium

Novel treatments for asthma - options for the many and the few

Date:  Sunday 26th March
1730 - 1900
Fee: Complimentary with ASM registration (sponsored by Boehringer Ingelheim Pty Limited)
Chair: Prof Christine Jenkins
Speakers: Prof Peter Wark, Prof Eric Bateman and Prof Alvin Ing

Asthma is one of the most common chronic diseases in Australia.  Despite effective treatments being available, almost half of Australian patients remain poorly controlled and therefore asthma continues to present a significant burden, in particular for young children and for chronic severe asthma, there are only limited options available with an acceptable risk-benefit profile for often life-long treatment. In 2015 alone, it was estimated that the total costs of asthma in Australia alone were almost $28bn, including $1.2bn of direct healthcare costs. With that in mind, it is clear that we need to improve our management of asthma including more novel and affordable treatment options to address this unmet need.
Over the past few years, we have increased our understanding of the different asthma phenotypes and endotypes, and as a result have developed some highly targeted and individualised therapeutics with many more still in development.  In addition there is growing interest in the role of anticholinergics in the treatment of asthma. The full clinical development programme in adult and paediatric asthma for tiotropium has recently been completed and includes 18 trials in over 6000 patients from as young as one year of age, marking the introduction of the first new class of inhaled maintenance treatment for asthma in over 25 years.  Bronchial thermoplasty is yet another novel and promising intervantion for asthma.  Recent data have demonstrated long-term safety and sustained efficacy of this procedure.  But which patients are likely to benefit most?
The future is indeed promising, but there is still work to be done and questions to be answered.  This symposium will review some novel treatment approaches for the management of symptomatic asthma and discuss options for the many and the few.

Breakfast with the editors

Date:  Tuesday 28th March
0700 - 0815
Fee: $40 per person. Indicate your attendance when registering for the Meeting.
Chairs: Paul Reynolds & Philip Bardin
Speakers: Christopher Cates, Alaina Ammit, Jane Bourke, Matthew Naughton

What is the worst paper you have ever published? What is the code of author position? Where should I be? What are the fundamentals of good publishing? Join Editors of basic and clinical journals in a candid discussion around the pathways, etiquette and tribulations of publishing. Get tips on targeting different journals for your work, submitting your manuscripts, responding to reviewers, and getting published. Find out what editors are really looking for in manuscript submissions!
Dr Christopher Cates is the co-ordinating editor of the Cochrane Airways Review Group.
Prof Alaina Ammitt is an Editorial Board Member of the journals Allergy and Respiratory Research.
Prof Matthew Naughton has served on the editorial boards of American Journal of Respiratory and Critical Care Medicine & SLEEP, as well as the TSANZ representative on the Internal Medicine Journal.
Dr Jane Bourke is on the editorial board of Scientific Reports - open access journal from the publishers of Nature.

GSK Breakfast Symposium

Real-life Evidence Generation and Evaluation of Therapeutics

Date:  Sunday 26th March
0700 - 0815
Fee: Complimentary with ASM registrations (sponsored by GSK)
Chair: Prof John Upham
Speakers: Prof Helen Reddel and Prof Christine Jenkins

Randomised Controlled Trials (RCTs) are considered to be the ‘gold standard’ for evaluating treatment outcomes and providing information on the treatment’s ‘efficacy’. They are designed to test a therapeutic hypothesis under optimal conditions in the absence of confounding factors. RCTs have high internal validity, but low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies provide information on the ‘effectiveness’ of a treatment; the measure of the extent to which an intervention does what is intended to do in routine clinical practice. At variance to RCTs, these trials have high generalizability, but low internal validity. The number of real life studies is increasing in different areas of respiratory medicine, particularly in asthma and COPD. The proposed GSK symposium will address this important topic. 

Real life research and its importance in respiratory medicine
Presented by Prof Helen Reddel

Effect of fluticasone furoate/vilanterol in everyday clinical practice: COPD Salford Lung Study
Presented by Prof Christine Jenkins

Novartis Breakfast Symposium

Phenotypes of COPD and Asthma: Why does it matter?

Date:  Monday 27th March
0700 - 0815
Fee: Complimentary with ASM registration (sponsored by Novartis)
Chair: Prof Christine McDonald
Speakers: Prof David Price and Prof Jo Douglass

COPD and Severe Asthma are heterogeneous diseases. As the number of treatments for COPD and asthma continues to grow, physicians have the opportunity to practice an individualized approach to diagnosis and treatment, which can improve outcomes and quality of life for patients. Clinicians first need to understand and determine the distinct phenotypes which represent the disorders that make up the syndromes of COPD and Severe Asthma in order to be able to target treatments specifically to individual patients. The objective of this symposium is to explain the underlying mechanisms behind the different COPD and Severe Asthma phenotypes, provide clarity on their identification and review the latest evidence for those targeted treatments.

Roche Products Pty Limited Evening Symposium

How can the MDT collaborate to optimise IPF patient outcomes in the evolving Australian treatment landscape?

Date:  Monday 27th March
  Drinks and canapes from 1730, session is from 1800 - 1930
Fee: Complimentary with ASM registration (sponsored by Roche Products Pty Limited)
Chair: A/Prof Tamera Corte (RPA, NSW)
• Prof Dr Steven Nathan (Director of the Advanced Lung Disease Program and Lung Transplant Program at Inova Fairfax Hospital, Virginia USA)
• A/Prof Daniel Chambers (Prince Charles Hospital, QLD)
• Dr Nicole Goh (Austin Hospital, VIC)
• Dr Samantha Ellis (ILD Radiologist - Alfred Hospital, VIC)

Idiopathic pulmonary fibrosis (IPF) is a progressive, unpredictable, and often rapidly fatal fibrosing lung disease with an estimated prevalence in Australia of approximately 5000 patients. The median survival time for this fatal disease is estimated between 3 and 5 years.
The pending broad access of anti-fibrotic treatment for IPF in Australia will raise some important clinical challenges. Multidisciplinary team (MDT) diagnosis is the current gold standard in interstitial lung disease (ILD) and is the recommended approach by international guidelines due to the diagnostic complexity. Recent studies have shown that MDT diagnosis provides greater accuracy/concordance than working alone and is imperative for appropriate patient management.
Four ILD case studies will be presented by A/Prof Dan Chambers and the diagnosis discussed by the multidisciplinary panel. Polling will provide the opportunity for audience interaction pre and post MDT discussion.
Prof Dr Steven Nathan will present his personalised treatment approach for the IPF cases presented in the first section of the symposium. He will share recently published evidence and reflect on how this and individual patient factors impact his clinical treatment decisions. He will also provide insight into how he discusses the therapy goals with individual patients and long-term management strategies.
Finally, the symposium will conclude with Dr Nicole Goh discussing the role of the other important multidisciplinary team members in the long-term management of IPF. She will share her experience on how transplant, pulmonary rehabilitation services and the specialist nurse can improve the long-term outcomes of patients.

Using Technology to Enhance Physical Activity Breakfast Symposium

Date:  Monday 27th March 
0700 - 0815
Fee: $40 per person. Indicate your attendance when registering for the Meeting.
Chair: Karen Royals
Speaker: Eileen Collins

Chronic obstructive pulmonary disease (COPD) is a debilitating disease that leads to increasing dyspnea and fatigue.  Increasing dyspnea, fatigue and muscle weakness lead to inactivity and the cycle continues. Physical inactivity is associated with multiple co-morbid conditions, increased hospitalizations and increased all-cause mortality. Increasing physical activity levels in patients with COPD is crucial to improving their overall health and well-being. This presentation will focus on physical activity in patients with COPD and how technology can be integrated into successful interventions focused on improving physical activity.

Vertex Pharmaceuticals (Australia) Pty Ltd Breakfast Symposium

Cystic Fibrosis - the road ahead

Date:  Tuesday 28th March
0700 - 0815
Fee: Complimentary with ASM registration (sponsored by Vertex Pharmaceuticals (Australia) Pty Ltd)
Chair: Assoc Prof Sarath Ranganathan; Director of Respiratory Medicine, Royal Children's Hospital

Debate 1: The lung microbiome drives new infections and outcomes in CF
For:  Assoc Prof Luke Hoffman; MD, PhD Pulmonary and Sleep Medicine, Cystic Fibrosis Research Seattle Children’s Hospital
Against: Assoc Prof Geraint Rogers; Director, Microbiome Research, Flinders Medical School

Debate 2:  The most important outcome measure in CF is FEV1
For: Prof Claire Wainwright; Respiratory Physician and Lead for Cystic Fibrosis, Lady Cilento Children’s Hospital Queensland and Chair of the Education and Training Sub-Committee of the TSANZ
Against: Dr Edward McKone; MSc, MD, FRCPI, BA, MB BCh, BAO, MRCPI  Clinical Associate Professor, School of Medicine, St Vincent’s University Hospital, Dublin, Ireland